Water-soluble porphyrins derived from 5,10,15,20-tetrakis(N-ethylpyridinium-3-yl)porphyrin: Metal center effect on the photodynamic activity against aggressive triple-negative breast cancer lineage
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Porphyrin and Phthalocyanine Chemistry · Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. IARC - marks breast cancer awareness month 2024
2. Exploring the potential of metallodrugs as chemotherapeutics for triple negative breast cancer10.1002/chem.202100438 ↗
3. Molecularly targeted therapies in breast cancer: a traditional review
4. Abordagem molecular no desenvolvimento de fármacos anti-tumorais
5. Photodynamic therapy of cancer: an update
6. Current advances in photodynamic therapy (PDT) and the future potential of PDT-combinatorial cancer therapies10.3390/ijms25021023 ↗
7. Photodynamic therapy review: principles, photosensitizers, applications, and future directions10.3390/pharmaceutics13091332 ↗
8. Photodynamic therapy review: past, present, future, opportunities and challenges10.3390/photochem4040027 ↗
9. Hematoporphyrin as a photosensitizer of tumors10.1111/j.1751-1097.1983.tb02687.x ↗
10. Photodynamic therapy for the treatment and diagnosis of cancer–a Review of the current clinical status10.3389/fchem.2021.686303 ↗
11. Dye sensitizers for photodynamic therapy10.3390/ma6030817 ↗
12. Cancer, photodynamic therapy and porphyrin-type derivatives10.1590/0001-3765201820170811 ↗
13. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD143310.1021/acs.chemrev.8b00211 ↗
14. A review of light sources and enhanced targeting for photodynamic therapy10.2174/0929867328666210121122106 ↗
15. Synthesis and antitumor activity of new porphyrin‐Platinum(II) complexes with the cytostatic platinum fragment attached to the porphyrin side chains10.1002/cber.1491271109 ↗
16. Platinum(II) complexes with porphyrin ligands—additive cytotoxic and photodynamic effect10.1002/anie.199422141 ↗
17. Uptake and light-induced cytotoxicity of hyaluronic acid-grafted liposomes containing porphyrin in tumor cells10.1016/j.jddst.2018.06.024 ↗
18. Benzamide porphyrins with directly conjugated and distal pyridyl or pyridinium groups substituted to the porphyrin macrocycles: study of the photosensitising abilities as inducers of apoptosis in cancer cells under photodynamic conditions10.1016/j.jphotobiol.2017.11.014 ↗
19. Combination of photodynamic therapy and gene silencing achieved through the hierarchical self-assembly of porphyrin-siRNA complexes10.1016/j.ijpharm.2019.118585 ↗
20. Brandon · 2019
21. Tetracationic porphyrin derivatives against human breast cancer10.1016/j.jphotobiol.2021.112258 ↗
22. Using porphyrins as albumin-binding molecules to enhance antitumor efficacies and reduce systemic toxicities of antimicrobial peptides10.1016/j.ejmech.2021.113382 ↗
23. Synthesis and biological properties of EGFR-targeted photosensitizer based on cationic porphyrin10.3390/pharmaceutics15041284 ↗
24. Synthesis and in vitro testing of hematoporphyrin type ligands in Platinum(II) complexes as potent cytostatic and phototoxic antitumor agents10.1016/S0020-1693(97)05593-X ↗
25. Double porphyrin platinum conjugates10.1515/znb-2002-0707 ↗
26. New porphyrin platinum conjugates for the cytostatic and photodynamic tumor therapy10.1016/S0020-1693(02)01490-1 ↗
27. Porphyrin platinum conjugates – new aims10.1016/S0020-1693(03)00479-1 ↗
28. Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells10.1021/bi049272v ↗
29. Nuclear estrogen receptor targeted photodynamic therapy: selective uptake and killing of MCF‐7 breast cancer cells by a C17α ‐alkynylestradiol‐porphyrin conjugate10.1002/jcb.20955 ↗
30. Low concentrations of a non-hydrolysable tetra-S-glycosylated porphyrin and low light induces apoptosis in human breast cancer cells via stress of the endoplasmic reticulum10.1039/b806536e ↗
31. Meso -Tetrakis(p -sulfonatophenyl)N-confused porphyrin tetrasodium salt: a potential sensitizer for photodynamic therapy10.1021/jm300009q ↗
32. Reactivity and stability of metalloporphyrin complex formation: DFT and experimental study10.3390/molecules25184221 ↗
33. Photodynamic therapy and the development of metal-based photosensitisers10.1155/2008/276109 ↗
34. Photodynamic therapy of inorganic complexes for the treatment of cancer10.1111/php.13467 ↗
35. Metal-based photosensitizers for photodynamic therapy: the future of multimodal oncology?10.1016/j.cbpa.2019.10.004 ↗
36. Structurally similar porphyrins and porphyrazines perform differently under green or red light irradiation against non-melanoma skin tumor cells10.1016/j.dyepig.2024.112527 ↗
37. Exploring structure–activity relationships in photodynamic therapy anticancer agents based on Ir(III)-COUPY conjugates10.1021/acs.jmedchem.3c00189 ↗
38. Recent advances in innovative strategies for enhanced cancer photodynamic therapy10.7150/thno.54227 ↗
39. Differential coordination demands in Fe versus Mn water-soluble cationic metalloporphyrins translate into remarkably different aqueous redox chemistry and biology10.1021/ic3012519 ↗
40. High lipophilicity of meta Mn(III) N-Alkylpyridylporphyrin-based superoxide dismutase mimics compensates for their lower antioxidant potency and makes them as effective as ortho analogues in protecting superoxide dismutase-deficient Escherichia coli10.1021/jm900576g ↗
41. Methoxy-derivatization of alkyl chains increases the in vivo efficacy of cationic Mn porphyrins. Synthesis, characterization, SOD-like activity, and SOD-deficient E. coli study of meta Mn(III) N-methoxyalkylpyridylporphyrins10.1039/c0dt01321h ↗
42. Relationship among redox potentials, proton dissociation constants of pyrrolic nitrogens, and in vivo and in vitro superoxide dismutating activities of manganese(III) and iron(III) water-soluble porphyrins10.1021/ic990118k ↗
43. Optimizing Zn porphyrin-based photosensitizers for efficient antibacterial photodynamic therapy10.1016/j.pdpdt.2016.11.009 ↗
44. Electron spin resonance spectroscopic and spectrophotometric investigation of the binding of tetracationic porphyrins and porphyrazines with calf thymus DNA. Unequivocal evidence for intercalation10.1039/f29858101739 ↗
45. Electronic spectra, resonance raman spectra and solution properties of water-soluble Cu(II), Ni(II) and Co(III) porphyrins10.1016/S0020-1693(00)83942-0 ↗
46. Analytical application of porphyrins—I spectrophotometric determination of ultramicro amounts of copper with α,β,γ,δ-tetra-(3-N-methylpyridyl)porphine10.1016/0039-9140(77)80122-7 ↗
47. Spectra of porphyrins10.1016/0022-2852(61)90236-3 ↗
48. Facile synthesis of water-soluble cationic Tin(IV) porphyrins and water-insoluble Tin(IV) porphyrins in water at ambient temperature10.1246/bcsj.20160091 ↗
49. The coordination chemistry of tin porphyrin complexes10.1016/j.ccr.2004.01.004 ↗
50. Synthesis and reactivity of porphyrin complexes of group IV p-elements10.1023/A:1020407029048 ↗
51. Optical spectra and electronic structure of porphyrins and related rings
52. Synthesis and hydrogen-bonded supramolecular assembly of trans-dihydroxotin(IV) tetrapyridylporphyrin complexes10.5012/bkcs.2004.25.12.1869 ↗
53. UV-vis absorption spectra of Sn(IV)tetrakis(4-pyridyl) porphyrins on the basis of axial ligation and pyridine protonation10.1007/s00894-019-4166-5 ↗
54. Redox chemistry of gold(III) porphyrins in water10.1039/f29868202337 ↗
55. Gold porphyrin complexes. Evidence for electrochemically inert gold (III)10.1016/S0020-1693(00)87273-4 ↗
56. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure10.1002/chem.200902741 ↗
57. Synthesis and cytotoxicity study of gold(III) porphyrin complexes and their derivative in breast cancer cells10.1016/j.jscs.2021.101366 ↗
58. Spectral properties and solution behavior of Gold(III) coordination compounds with water-soluble porphyrins10.1134/S0036023616120196 ↗
59. How does the tin(IV)-insertion to porphyrins proceed in water at ambient temperature?: Re-investigation by time dependent 1H NMR and detection of intermediates10.1016/j.ica.2018.07.036 ↗
60. 2014
61. The influence of lipophilicity in drug discovery and design10.1517/17460441.2012.714363 ↗
62. Amphiphilic cationic Zn-porphyrins with high photodynamic antimicrobial activity10.2217/fmb.14.148 ↗
63. Bioavailability of metalloporphyrin-based SOD mimics is greatly influenced by a single charge residing on a Mn site10.3109/10715762.2010.522575 ↗
64. Effect of molecular characteristics on cellular uptake, subcellular localization, and phototoxicity of Zn(II) N-Alkylpyridylporphyrins10.1074/jbc.M113.511642 ↗
65. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential10.1089/ars.2009.2876 ↗
66. Lipophilicity of potent porphyrin-based antioxidants: Comparison of ortho and meta isomers of Mn(III) N-alkylpyridylporphyrins10.1016/j.freeradbiomed.2009.04.002 ↗
67. Luminescence of porphyrins and metalloporphyrins. Part 2.—Copper(II), chromium(III), manganese(III), iron(II) and iron(III) porphyrins10.1039/f19817700369 ↗
68. Dynamics of the exciplex formation and decay between excited CuTMpyP4+ and thymine C=O groups of short oligothymidylates
69. Luminescence of porphyrins and metalloporphyrins. Part 4.—Fluorescence of substituted tetraphenylporphyrins10.1039/F29817701695 ↗
70. Luminescence of porphyrins and metalloporphyrins. Part 3.—Heavy-atom effects10.1039/F29817701281 ↗
71. Photochemistry of water-soluble porphyrins: comparative study of isomeric tetrapyridyl- and tetrakis(N-methylpyridiniumyl)porphyrins10.1021/ic00184a019 ↗
72. Photochemistry of metalloporphyrins in aqueous solutions10.1016/0584-8539(89)80232-6 ↗
73. Lakowicz · 2006
74. Solvent dependent photophysical properties of free base tetrapyridylporphyrin10.1016/j.molliq.2014.11.001 ↗
75. Mechano-stimulus and environment-dependent circularly polarized TADF in chiral Copper(I) complexes and their application in OLEDs10.1021/jacs.2c09458 ↗
76. Balzani · 2014
77. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy10.1039/cs9952400019 ↗
78. Exploiting radical-pair intersystem crossing for maximizing singlet oxygen quantum yields in pure organic fluorescent photosensitizers10.1039/D0SC03128C ↗
79. Luminescence of porphyrins and metalloporphyrins. Part 1.—Zinc(II), nickel(II) and manganese(II) porphyrins10.1039/f19807601978 ↗
80. Photo-oxidation of metalloporphyrins in aqueous solution10.1039/f19837901335 ↗
81. Photophysical, electro- and spectroelectro-chemical properties of the nonplanar porphyrin [ZnOEP(Py)44+,4Cl-] in aqueous media10.1016/j.jphotochem.2010.04.019 ↗
82. Synthesis, photophysics, computational approaches, and biomolecule interactive studies of metalloporphyrins containing pyrenyl units: influence of the metal center
83. Two-stage ligand exchange in Mn(III)-based porphyrinic metal−organic frameworks for fluorescence water sensing10.1016/j.snb.2022.131808 ↗
84. Enhancing porphyrin photostability when locked in metal–organic frameworks10.1039/C8DT03638A ↗
85. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy10.1016/j.apsb.2017.09.003 ↗
86. Terapia fotodinâmica: aspectos farmacológicos, aplicações e avanços recentes no desenvolvimento de medicamentos10.1590/S0100-40422002000500016 ↗
87. Human embryonic kidney 293 cells: a vehicle for biopharmaceutical manufacturing, structural biology and electrophysiology10.1159/000485501 ↗
88. Anticancer therapeutic potential of Mn porphyrin/ascorbate system10.1016/j.freeradbiomed.2015.10.416 ↗
89. An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols10.1073/pnas.1915202117 ↗
90. Synergetic anticancer activity of gold porphyrin appended to phenyl tin malonate organometallic complexes10.1039/D0DT03792C ↗
91. Ascorbate-dependent and ascorbate-independent Mn porphyrin cytotoxicity: anticancer activity of Mn porphyrin-based SOD mimics through ascorbate-dependent and -independent routes10.1080/13510002.2021.1917214 ↗
92. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells
93. Studying the cellular distribution of highly phototoxic platinated metalloporphyrins using isotope labelling10.1039/D0CC05196A ↗
94. Phototoxicity: its mechanism and animal alternative test methods10.5487/TR.2015.31.2.097 ↗
95. Philips. PL-L Essential 36W/865/4P 1CT/50 - energy-saving compact fluorescent non-integrated lamphttps://www.lighting.philips.com/api/assets/v1/file/Signify/content/927933686503_EU.en_AA.PROF.FP/Localized_commercial_leaflet_927933686503_en_AA.pdf. [Accessed 23 August 2025].
96. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery10.1016/j.ejca.2004.01.009 ↗
97. Recent advances in therapeutic strategies for triple-negative breast cancer10.1186/s13045-022-01341-0 ↗
98. Photodynamic therapy induced cell cycle arrest and cancer cell synchronization: review10.3389/fonc.2023.1225694 ↗
99. Design and properties of porphyrin‐based singlet oxygen generator10.1002/ijch.201500026 ↗
100. Photosensitized oxidation of 2′,7′-dichlorofluorescin: singlet oxygen does not contribute to the formation of fluorescent oxidation product 2′,7′-dichlorofluorescein10.1016/S0891-5849(02)00982-6 ↗